INS and diabetes mellitus: These GIPRdn transgenic mice exhibit an early disturbance in pancreatic islet development (severe reduction of beta-cell mass, disturbed composition of islets with alpha-, delta- and PP-cell hyperplasia and decreased islet neogenesis), diminished insulin secretion, hyperglucagonemia and early onset diabetes mellitus.